Home World News Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed... World News Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 18, 2025 483 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Understanding FDA Emergency Use Authorization January 21, 2021 Mom Thinks Baby Died Until Firefighters Say The Family Dog Made... June 4, 2019 ΟΓΚΟΙ ΕΓΚΕΦΑΛΟΥ February 10, 2019 Heine H. Hansen Award: Johan Vansteenkiste and Fiona Blackhall Honoured for... March 11, 2021 Load more HOT NEWS We have a Deal: What does the new UK-EU relationship mean... Evaluation of Pemigatinib Efficacy in FGFR-Altered Advanced Solid Tumours Led to... Banking on breakthroughs for children and young people ASCO Annual Meeting 2023: Radiation Therapy May Not Be Needed After...
